Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

MR BIOINVEST ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   2.7% 1.1% 2.2% 0.8% 1.6% 1.0% 7.7% 7.7%   Credit score (0-100)   62 86 66 90 74 86 32 32   Credit rating   BBB A BBB AA A A BB BB   Credit limit (kDKK)   0.0 1,018.4 1.0 2,091.4 51.1 1,510.6 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -64.0 -33.0 -82.0 -34.0 -28.0 -30.7 0.0 0.0   EBITDA   -64.0 -33.0 -82.0 -34.0 -28.0 -30.7 0.0 0.0   EBIT   -64.0 -33.0 -82.0 -34.0 -28.0 -30.7 0.0 0.0   Pre-tax profit (PTP)   -1,371.0 3,289.0 -102.0 3,500.0 -3,273.0 2,390.0 0.0 0.0   Net earnings   -1,371.0 2,865.0 -102.0 2,746.0 -2,554.0 1,861.8 0.0 0.0   Pre-tax profit without non-rec. items   -1,371 3,289 -102 3,500 -3,273 2,390 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   20,229 23,094 22,991 25,737 23,183 25,045 24,662 24,662   Interest-bearing liabilities   0.0 0.0 37.0 73.0 73.0 72.6 0.0 0.0   Balance sheet total (assets)   20,254 23,291 23,054 26,525 23,977 25,143 24,662 24,662   Net Debt   -18,754 -20,295 -17,129 -18,404 -14,023 -14,546 -24,662 -24,662     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -64.0 -33.0 -82.0 -34.0 -28.0 -30.7 0.0 0.0   Gross profit growth   -28.0% 48.4% -148.5% 58.5% 17.6% -9.6% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   20,254 23,291 23,054 26,525 23,977 25,143 24,662 24,662   Balance sheet change%   -8.1% 15.0% -1.0% 15.1% -9.6% 4.9% -1.9% 0.0%   Added value   -64.0 -33.0 -82.0 -34.0 -28.0 -30.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   5.0% 15.2% 3.6% 14.3% 6.3% 9.8% 0.0% 0.0%   ROI %   5.0% 15.3% 3.7% 14.5% 6.5% 9.9% 0.0% 0.0%   ROE %   -6.6% 13.2% -0.4% 11.3% -10.4% 7.7% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   99.9% 99.2% 99.7% 97.0% 96.7% 99.6% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   29,303.1% 61,500.0% 20,889.0% 54,129.4% 50,082.1% 47,420.5% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.2% 0.3% 0.3% 0.3% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   1,573.4% 0.0% 5,108.1% 63.6% 6,667.1% 18.6% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   750.2 103.0 275.5 23.4 19.1 154.9 0.0 0.0   Current Ratio   750.2 103.0 275.5 23.4 19.1 154.9 0.0 0.0   Cash and cash equivalent   18,754.0 20,295.0 17,166.0 18,477.0 14,096.0 14,618.8 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,647.0 914.0 361.0 -310.0 1,216.0 859.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0